华神科技拟定增募资不超过4.5亿元

Group 1 - The core point of the article is that Huasheng Technology plans to issue A-shares to a specific entity to raise funds for liquidity and debt repayment, with the share price set at 3.15 yuan per share, aiming to raise up to 450 million yuan [1][2] - The controlling shareholder of Huasheng Technology will change from Sichuan Huasheng Group to Chengdu Yuanhong Biotechnology, which is controlled by the actual controllers Huang Mingliang and Ouyang Ping [1] - Huasheng Technology's main business revenue is concentrated in the pharmaceutical sector, with a significant decline in revenue and a net loss reported for the first three quarters of 2025 [1] Group 2 - The Chinese medicine industry is entering a new development era, presenting broad prospects, but Huasheng Technology faces challenges in its existing business and needs to seek new breakthroughs [2] - The fundraising from the share issuance is expected to enhance the company's financial strength, respond to industry changes, and support ongoing R&D investments [2] - Previous failed fundraising attempts have created uncertainty, and the successful implementation of this new plan is crucial for the company's future [3]